title: The effect of selenium supplementation on outcome in very low birth weight infants: a randomized controlled trial. The New Zealand Neonatal Study Group.
abstract: BACKGROUND
  Low selenium (SE) status has been documented in preterm infants and has been suggested to be a risk factor for chronic lung disease.
  
  
  METHODS
  A total of 534 infants with birth weight <1500 g were enrolled in 8 New Zealand centers in a double-blind placebo-controlled randomized trial of SE supplementation from week 1 of life until 36 weeks' postmenstrual age or discharge home. Supplemented infants received 7 microg/kg/d of SE when fed parenterally and 5 microg/kg/d when fed orally. Plasma SE and glutathione peroxidase concentrations were measured in mothers after delivery and in infants before randomization and at 28 days and 36 weeks' postmenstrual age. Primary outcome measures were oxygen dependency at 28 days and total days oxygen dependency.
  
  
  RESULTS
  No significant differences were seen between the groups with respect to primary or secondary outcome measures, with the exception that fewer supplemented infants had an episode of sepsis after the first week of life (P <.038). Mean plasma SE concentrations were 0.33 micromol/L before randomization in both groups and at 28 days had risen in the supplemented group (0.56 micromol/L) but fallen in the control group (0.29 micromol/L) (P <.0001). There was no association between outcome measures and SE concentrations at 28 days or 36 weeks' postmenstrual age. However, lower maternal and infant prerandomization SE concentrations were associated with increased respiratory morbidity.
  
  
  CONCLUSIONS
  Postnatal SE supplementation in very low birth weight infants did not improve neonatal outcome. Further investigation of SE supplementation of mothers from the second half of pregnancy is warranted.
authors.affiliation: Departments of Pediatrics, Pathology, and Public Health, Christchurch School of Medicine, Christchurch, New Zealand.
authors.forename: B A
authors.initials: BA
authors.lastname: Darlow
authors.forename: C C
authors.initials: CC
authors.lastname: Winterbourn
authors.forename: T E
authors.initials: TE
authors.lastname: Inder
authors.forename: P J
authors.initials: PJ
authors.lastname: Graham
authors.forename: J E
authors.initials: JE
authors.lastname: Harding
authors.forename: P J
authors.initials: PJ
authors.lastname: Weston
authors.forename: N C
authors.initials: NC
authors.lastname: Austin
authors.forename: D E
authors.initials: DE
authors.lastname: Elder
authors.forename: N
authors.initials: N
authors.lastname: Mogridge
authors.forename: I H
authors.initials: IH
authors.lastname: Buss
authors.forename: K B
authors.initials: KB
authors.lastname: Sluis
mesh_terms: D004311:Double-Blind Method; D005260:Female; D005979:Glutathione Peroxidase / Q000097:blood; D006801:Humans; D006819:Hyaline Membrane Disease / Q000097:blood / Q000628:therapy; D007223:Infant; D007231:Infant, Newborn; D019102:Infant, Very Low Birth Weight; D008297:Male; D010102:Oxygen Inhalation Therapy; D010288:Parenteral Nutrition; D011247:Pregnancy; D011256:Pregnancy Outcome; D012643:Selenium / Q000008:administration & dosage* / Q000097:blood; D013997:Time Factors
chemical_list: D005979:Glutathione Peroxidase; D012643:Selenium